ArticlePLoS computational biology2021
Bridging the gap: Using reservoir ecology and human serosurveys to estimate Lassa virus spillover in West Africa.
Article in PLoS computational biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Assessing the Environmental Drivers of Lassa Fever in West Africa: A Systematic Review.Viruses · 2025Pooled it
- Lassa Virus-A Persistent and Evolving Threat.Microorganisms · 2026Review
- Temporal dynamics, climate associations, and surveillance performance of Lassa fever in Nigeria, 2020-2025: a national longitudinal analysis.Osong public health and research perspectives · 2026Article
- Sirtuin 1 Is Required for Optimal Mammarenavirus Multiplication.bioRxiv : the preprint server for biology · 2026Article
- Emerging Mammarenaviruses in Wildlife: Expanding Host Range and Implications.Animals : an open access journal from MDPI · 2026Review
- Local Knowledge of Land Use Effects on Human-Rodent Interfaces in Lassa-Endemic Nigeria.EcoHealth · 2026Article
- The socio-economic shield limits Lassa virus spillover in urban West Africa.Epidemiology and infection · 2026Article
- Evaluating vectors for the design of a spillover-disrupting Lassa virus transmissible vaccine.PLoS computational biology · 2026Article
- Assessing Evidence to Guide Primary Prevention of Pathogen X.Emerging infectious diseases · 2026Article
- Non-Mastomys rodents harbour ancient Lassa virus lineages within Benin and Nigeria's Guinea savanna belt.Scientific reports · 2026Article
- Local heterogeneity in Lassa fever serology in rural Nigeria: Implications for vaccine trial site selection.PLoS neglected tropical diseases · 2026Article
- Climate-driven changes in zoonotic risk of arenaviral hemorrhagic fevers in South America.Npj viruses · 2026Article
- Regional Lassa virus lineages select for divergent MHC-I repertoires in Mastomys natalensis rodents.PLoS pathogens · 2026Article
- Site-1 protease mediated GPC processing is required for persistence of LCMV Clone 13.Npj viruses · 2026Article
- Pathogen host jump risk is not predicted by spillover rate, but rather by novelty.PLoS biology · 2026Article
- Avian Metapneumovirus: Virology, Epidemiology, and Insights from a Comparative Analysis with Human Metapneumovirus-A Review.Biomolecules · 2026Review
- Lassa virus circumvents macrophage and dendritic cell antiviral defences in its natural reservoir, the Natal multimammate mouse (Mastomys natalensis).Npj viruses · 2026Article
- Article
- Land use gradients drive spatial variation in Lassa fever host communities in the Eastern Province of Sierra Leone.The Journal of animal ecology · 2026Article
- Screening of the Pandemic Response Box Library Identified CRM1/XPO1 as an Anti-Mammarenavirus Druggable Target.Viruses · 2026Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Forecasting the risk of pathogen spillover from reservoir populations of wild or domestic animals is essential for the effective deployment of interventions such as wildlife vaccination or culling. Due to the sporadic nature of spillover events and limited availability of data, developing and validating robust, spatially explicit, predictions is challenging. Recent efforts have begun to make progress in this direction by capitalizing on machine learning methodologies. An important weakness of existing approaches, however, is that they generally rely on combining human and reservoir infection data during the training process and thus conflate risk attributable to the prevalence of the pathogen in the reservoir population with the risk attributed to the realized rate of spillover into the human population. Because effective planning of interventions requires that these components of risk be disentangled, we developed a multi-layer machine learning framework that separates these processes. Our approach begins by training models to predict the geographic range of the primary reservoir and the subset of this range in which the pathogen occurs. The spillover risk predicted by the product of these reservoir specific models is then fit to data on realized patterns of historical spillover into the human population. The result is a geographically specific spillover risk forecast that can be easily decomposed and used to guide effective intervention. Applying our method to Lassa virus, a zoonotic pathogen that regularly spills over into the human population across West Africa, results in a model that explains a modest but statistically significant portion of geographic variation in historical patterns of spillover. When combined with a mechanistic mathematical model of infection dynamics, our spillover risk model predicts that 897,700 humans are infected by Lassa virus each year across West Africa, with Nigeria accounting for more than half of these human infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.